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In 2016, the World Health Assembly of the World Health Organisation 
approved the first Global Health Sector Strategy to eliminate viral 
hepatitis. The aim of the strategy is to eliminate viral hepatitis by 2030, 
and was defined as a 90% reduction in the incidence of new infections 
with a consequent 65% reduction in mortality from associated liver 
disease.[1] Globally, the prevalence of hepatitis C virus (HCV) is 1%, 
equating to an estimated 71.1 million people with active hepatitis C 
viraemia and resulting in HCV being a leading cause of chronic liver 
disease. The global burden of liver disease continues to increase as a 
result of hepatitis C-related cirrhosis, hepatocellular carcinoma, liver 
failure and death.[2] The epidemiology and prevalence of chronic 
HCV infection in South Africa (SA) remain poorly characterised 
and understood. Few data exist on defined cohorts of patients with 
chronic HCV and responses to therapy. The modelled prevalence of 
HCV viraemia in SA, as of 2015, was 0.4 - 0.9%, with genotype (GT) 
1b (22.1%) thought to be most frequent, although GTs 1 - 5 were 
prevalent.[2]
Following the identification and sequencing of HCV in 1989 by 
Choo et al.,[3] the management of chronic HCV infection has 
undergone a revolution. Initially, treatment with standard interferon 
yielded poor response rates.[4] Consequently, pegylated interferon 
and oral ribavirin (Peg-IFN/RBV) enhanced response, with sustained 
virological response (SVR) rates of ~50%.[5] Despite improved SVR 
rates, treatment was costly and associated with significant adverse 
effects that resulted in patients discontinuing therapy. Cytopenias 
associated with drug toxicities sometimes necessitated erythropoietin 
(EPO) and/or granulocyte-macrophage colony-stimulating factor 
(GM-CSF) to support treatment sustainability.[5] Factors influencing 
a positive treatment outcome included the ability to complete >80% 
of the planned duration of treatment with >80% of the required doses 
of Peg-IFN and RBV,[6] the IL28B polymorphism, and the baseline 
viral load, degree of liver fibrosis and GT. In 2012, the first of a 
new generation of add-on oral protease inhibitors (PIs), specifically 
for GT-1 HCV, emerged. These drugs, telaprevir and boceprevir, 
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Background. Hepatitis C virus (HCV) in South Africa (SA) is incompletely characterised and understood. Epidemiological and clinical 
data will better inform our understanding and assist national policy decision-making. Against the background of more than two decades of 
clinical challenges in HCV management, the advent of direct-acting antivirals (DAAs) now makes HCV elimination plausible.
Objectives. To better understand the base from which we come, we elected to review and characterise our HCV experience at Groote Schuur 
Hospital (GSH), Cape Town, SA, in the pegylated interferon (Peg-IFN) and ribavirin (RBV) management era.
Methods. Patients with chronic HCV infection attending the GSH Liver Clinic from 2002 to 2014 were included in the analysis. Relevant 
data were extracted from a registry and existing clinical records were accessed. Two brands of Peg-IFN were available, and patients treated 
with the first-generation add-on protease inhibitor telaprevir were included.
Results. A total of 238 patients were included in the analysis (median (interquartile range) 47 (37 - 58) years, 60.5% males). Males were 
significantly younger than females (43.5 (35 - 52) years v. 55 (42 - 64) years, respectively) (p<0.0001). The majority were white (55.9%) or 
of mixed ancestry (21.8%), 16.4% were HIV co-infected, 3.7% were hepatitis B virus (HBV) co-infected, and 1 patient (0.4%) was triple-
infected with HCV, HBV and HIV. The most likely mode of HCV acquisition was blood or blood product exposure prior to 1992 (32.8%) 
and injecting drug use (17.6%), while 30.3% of patients had no clear risk factor identifiable. Genotypes (GTs) 1 - 5 were observed, with GT-1 
(34.9%) predominating. Of patients who were biopsied (n=90), 30.0% had ≥F3 fibrosis, with 15.6% cirrhotic. With IL28B polymorphisms, 
the heterozygous CT (23.9%) and CC (15.5%) genotypes were most frequent. Of the patients, 32.6% accessed Peg-IFN/RBV-based therapy, 
6.5% (n=5) with add-on telaprevir. GT-1 (35.1%) was most prevalent in the treatment group, followed by GT-3 (26.0%) and GT-5 (18.2%); 
10.0% were HIV co-infected. The overall sustained virological response (SVR) rate was 75.3%, with 37.0% of GT-1 patients not achieving 
SVR. Of the patients treated, 49.4% experienced adverse events, including cytopenias (32.5%) and depression (15.6%), and 23.4% required 
cell support in the form of erythropoietin and/or granulocyte-macrophage colony-stimulating factor.
Conclusions. HCV patients in the Peg-IFN/RBV management era typified the epidemiology of HCV. GT distribution was pangenotypic, 
and treatment outcomes were encouraging despite treatment challenges. Patient selection, IL28B and sensible support of cytopenias 
probably accounted for these favourable outcomes. However, numbers treated were limited, and the DAA era of therapy allows for rapid 
expansion of therapy with now growing numbers of patients and a changing local epidemiology.
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significantly improved SVR rates, but at the expense of enhanced 
adverse effects.[7-9] The advent of the oral direct-acting antivirals 
(DAAs) for hepatitis C has revolutionised therapy, with SVR rates 
now exceeding 95% with fewer adverse effects. The success of DAA 
therapy has made HCV elimination now very plausible.
Peg-IFN/RBV initially became available in SA in 2002, and by 2004 
the University of Cape Town/Groote Schuur Hospital (UCT/GSH) 
Liver Clinic was able to access this standard of care for HCV-infected 
individuals via several mechanisms including compassionate use or 
expanded access treatment programmes, a hospital-allocated budget 
to treat a limited number of HCV-infected individuals annually, or 
private funding.
Objectives
Given the advent of the DAA era of treatment, we elected to 
review and describe our experience with interferon-based therapy 
over a decade-plus period from 2002 to 2014. We document our 
local experience with regard to patient demographics, the clinical, 
biochemical and genetic profile of the study population, viral 
characteristics, and treatment outcomes (side-effect profile and SVR 
rates) with interferon-based therapy during this period. No such data 
exist for SA, and reviewing our experience serves as a benchmark 
with which to compare the rapidly expanding, albeit currently 
limited, DAA era of HCV treatment in SA. This study therefore 
serves to inform national policy decision-making structures of the 
base from which we have functioned with regard to hepatitis C in SA. 
Given the need for data in informing such policy, this study aimed 
to support such policy structures in achieving SA’s efforts for viral 
hepatitis elimination by 2030.
Methods
All patients with HCV infection attending the UCT/GSH Liver Clinic 
from 2002 up to and including 2014 were included. All relevant 
patient demographic data and clinical characteristics were extracted 
from a patient registry, in addition to existing clinical records, and 
recorded in a database. In terms of treatment, two brands of Peg-IFN, 
viz. Peg-IFN α-2b (Peg-IntronR; Schering-Plough) and Peg-IFN α-2a 
(PegasysR; Hoffman-La Roche) were available in SA during the study 
period, and patients using either product were included. Standard 
Peg-IFN/RBV treatment guidelines based on GT were followed. 
Patients treated with the addition of the first-generation DAA therapy 
(telaprevir) to their Peg-IFN/RBV regimen were also included in the 
final analysis.
Laboratory tests
All baseline biochemical values, a full blood count and the 
international normalised ratio were recorded. HIV status was 
confirmed by enzyme-linked immunosorbent assay testing for HIV 
antibody and p24 antigen, and in patients who were HIV co-infected, 
the CD4+ count (cells/µL) was recorded at the time of presentation. 
Viral serological testing (ARCHITECT I or II; Abbott Diagnostics, 
USA) for hepatitis C (hepatitis C IgG antibody) was positive in 
all patients, and active viraemia was confirmed by an in-house 
polymerase chain reaction technique amplifying the 5′NCR region of 
HCV. Genotype was determined using the Versant HCV Genotype 
v2.0 Line Probe Assay (Siemens AG, Germany) or through in-house 
NS5B sequencing. HCV viral loads were measured using the COBAS 
Ampliprep/Cobas TaqMan v2.0 (Roche Diagnostics, Switzerland). 
Serological testing for hepatitis A (hepatitis A immunoglobulin G 
(IgG) antibody) and hepatitis B (hepatitis B surface antigen, HBcore 
IgG and core immunoglobulin M antibody) was performed.
Liver biopsy was used to assess fibrosis unless contraindicated 
(e.g. in haemophiliacs or coagulopathic patients). Liver biopsies 
were all assessed by one of two experienced liver histopathologists, 
while clinicopathological assessments were done concurrently with 
hepatologists. Hepatitis C was staged and graded using the METAVIR 
scoring system.
Ethical considerations
The study was approved by the University of Cape Town Human 
Research Ethics Committee (ref. no. HREC R045/2014).
Statistical analysis
Values are expressed as medians and interquartile ranges (IQRs) for 
continuous variables. Clinical characteristics are summarised using 
standard descriptive characteristics. Where appropriate, differences 
between qualitative parameters were explored using the Wilcoxon 
rank-sum test. Statistical analysis was performed using Excel 2013 
(Microsoft, USA).
Results
A total of 238 patients were evaluated, the majority male (60.5%, 
n=144) (Table 1). The median (IQR) age of the cohort was 47 (37 - 
58) years, but men were significantly younger than women (43.5 
(35 - 52) years v. 55 (42 - 64) years, respectively) (p<0.0001). Of 
note, self-identified heterosexual male patients were significantly 
older than men who have sex with men (MSM) (49 (47 - 51) years 
v. 40.5 (34 - 45) years, respectively) (p=0.0002). The majority of the 
patients were white (55.9%), followed by mixed ancestry (21.8%) 
and black African (13.9%). The probable mode of HCV acquisition 
was predominantly blood or blood product exposure prior to 1992 
(32.8%), parenteral through injecting drug use (IDU) (17.6%), 
or parenteral or percutaneous exposure (10.9%), e.g. needlestick 
injuries, tattoos, etc. Haemophiliacs comprised 13.4% of patients. 
No clear route could be identified in almost a third of patients 
(30.3%). In terms of GT distribution (Table 2), GT-1 (34.9%) 
predominated, with GT-1a more prevalent than GT-1b (62.7% 
v. 36.3%, respectively). GTs 3, 4 and 5 were present in similar 
frequencies (18.1%, 17.2%, and 16.0%, respectively), with GT-2 
least frequent (6.7%). GT was not identified in 7.1% of the cohort. 
The median hepatitis C viral load was 5.6 (4.7 - 6.2) log10 IU/mL. In 
addition, 16.4% of the patients were HIV co-infected, with a median 
baseline CD4+ count of 395 cells/µL, 3.7% (n=8) were hepatitis B 
co-infected, and 1 patient (0.4%) was triple-infected with HIV, HBV 
and HCV. Of patients screened for hepatitis A immunity (anti-HAV 
IgG), 71.5% were positive.
Baseline laboratory characteristics, shown in Table 3, demonstrate 
that median baseline alanine transaminase (ALT) and aspartate 
transaminase were elevated; however, 29.8% of patients (n=71) had 
an ALT level within the laboratory ‘normal’ range. Liver biopsy 
results are listed in Table 4 (n=90). In terms of the METAVIR score, 
30.0% of patients had ≥F3 fibrosis, with 15.6% cirrhotic. Most had 
F2 fibrosis. Ancillary biopsy data demonstrated a high frequency of 
steatosis (63.3%), and iron overload was present in 12.2%.
Table 5 notes all ancillary clinical or laboratory data. From 2011, 
all patients were screened for the IL28B allele. The heterozygous 
IL28B CT allele was most frequent, followed by the homozygous CC 
or TT alleles. Homozygosity or heterozygosity for the HFE C282Y 
or H63D alleles are highlighted, with homozygosity infrequently 
observed. Diabetes mellitus was highly prevalent (17.6%). Although 
alcohol consumption was not accurately assessed, 16.4% of patients 
confirmed regular consumption.
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Only 32.3% (n=77) of HCV-infected patients accessed Peg-IFN/
RBV-based therapy (Table 6). Five patients received add-on first-
generation PI treatment, viz. telaprevir. These 5 patients were all 
GT-1, and 2 of them had previously failed treatment. GT distribution 
in the treatment group was as follows: GT-1 35.1%, GT-2 11.7%, GT-3 
26.0%, GT-4 9.1% and GT-5 18.2%. Eight treated patients (10.4%) 
were HIV co-infected, and 1 was triple-infected. Most patients 
(71.5%) treated had ≥F2 fibrosis (Table 7), with 28.6% ≥F3 and 14.3% 
compensated cirrhotics. The overall SVR was 75.3%, with more than 
half of the patients (55.8%) achieving rapid virological response 
(RVR) and 84.4% achieving early virological response (EVR). Of 
the 19 patients not achieving SVR, the majority (52.6%) were GT-1. 
All GT-2 patients achieved SVR. Of patients tested for IL28B prior 
to treatment, 77.4%, 66.1% and 40.3% of the CC, CT and TT GTs, 
respectively, achieved SVR. The median (IQR) HCV viral load (log 
copies/mL) did not differ between those who did and did not achieve 
SVR (5.85 (5.0 - 6.4) and 5.8 (5.45 - 6.45), respectively) (p=0.56).
Table 8 demonstrates the event rate of adverse effects related to 
Peg-IFN/RBV therapy, with 49.4% of patients experiencing adverse 
effects. Surprisingly, only a single patient discontinued therapy 
because of adverse effects. The need for cytopenia support was 
substantial, with 7.8% and 7.8% of patients, respectively, requiring 
EPO for anaemia to maintain the RBV dose or GM-CSF support 
to maintain the Peg-IFN dose for treatment-related neutropenia. 
An equal number of patients required a combination of EPO 
and GM-CSF (7.8%). Psychiatric side-effects, especially depression, 
affected 15.6% of patients.
Discussion
There are several observations consistent with typical patterns of 
HCV epidemiology in our Liver Clinic cohort during the period 
2002 - 2014. Data now support the existence of two distinct 
epidemiological patterns of infection that create a bimodal age 
distribution for chronic hepatitis C.[10] The first group are older 
and probably acquired infection through a variety of mechanisms 
including blood or blood product exposure pre-1992, IDU and other 
parenteral modes of infection. This pattern is clearly reflected in our 
cohort, with one-third having had blood or blood product exposure 
prior to 1992. Less represented are recent or current IDUs, who are 
less likely to present or be referred for therapy given the rigours of Peg-
IFN/RBV-based therapy. Current transmission, in younger patients, 
is driven predominantly by IDUs and MSM, especially if HIV-
infected. [11] Consistent with known global HCV epidemiology, in our 
study men were younger than women, and MSM were significantly 
younger than non-MSM. In addition, we have previously documented 
high rates of HCV infection in HIV-positive MSM in Cape Town.[12-14]
Globally GTs 1 and 3 predominate, being responsible for 44% 
and 25%, respectively, of global HCV infection.[2] In a recent SA 
study of HCV characteristics in blood donors and the general 
population for the period 2008 - 2011, GT-1 was observed in 34%, 
with GT-5a being most prevalent (36%). GT-5a accounted for 54% 
of infections in black South Africans, with GT-1 seen in 43% of 
white South Africans. GTs 3 and 4 occurred at the same frequency 
(14%), and least frequent was GT-2.[11-16] The GT distribution in our 
patient cohort was fairly similar, except for GT-5a. This finding is 
not unexpected given the generally higher prevalence of GT-5a in 
the northern half of SA. GT-1 is invariably more prevalent in the 
southern portion of the country. Similarly, GT-4 was more prevalent 
compared with HCV GT distribution studies of the 1990s.[17] This 
probably reflects patterns of immigration into SA of people from 
GT-4-predominant parts of Africa over the past 2 - 3 decades. The 
GT-4 subtype variation also supports this notion. Furthermore, our 
Table 1. Demographic characteristics of the study population (N=238)
Parameter p-value
Male, n (%) 144 (60.5)
Heterosexual,* n (%) 112 (47.1)
MSM,* n (%) 32 (13.4)
Age† distribution, median (IQR)
Total cohort 47 (37 - 58)
Male/female 43.5 (35 - 52)/55 (42 - 64) 0.0001
Heterosexual/MSM 49 (47 - 51)/40.5 (34 - 45) 0.0002
Ethnicity,‡ n (%)
Asian 20 ( 8.4)
Black 33 (13.9)
Mixed ancestry 52 (21.8)
White 133 (55.9)
Mode of acquisition of HCV, n (%)
Transfusions§ 78 (32.8)
Unknown 72 (30.3)
IDU 42 (17.6)
Parenteral/percutaneous 26 (10.9)
Unsafe medical procedures¶ 13 (5.5)
Sexual encounter 5 (2.1)
Perinatal, mother to child 2 (0.8)
Haemophiliac, n (%) 32 (13.4)
MSM = men who have sex with men; IQR = interquartile range; HCV = hepatitis C virus; IDU = injecting drug use.
*Sexual orientation was self-reported.
†Age (years) at presentation.
‡Ethnicity was self-reported.
§Blood and blood products, including haemophiliacs.
¶Surgical/dental/orthodontic procedures.
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study again reinforces the HCV pangenotypic status (GTs 1 - 5) of 
SA, which has implications for elimination programmes based on 
DAA therapy in the future.
In terms of mode of HCV acquisition, IDU and blood or blood 
product exposure dominated. This finding is unsurprising, but in a 
considerable proportion of patients, no clear mode was identifiable. 
Factors such as traditional or unsafe medical practices may account 
for these patients’ hepatitis C. Not identifying a mode of transmission 
creates substantial difficulty when making recommendations on 
population screening for hepatitis C in SA as part of a national 
elimination strategy.
The median ALT, as anticipated, was elevated; however, the cohort 
demonstrates the phenomenon of a laboratory ‘normal’ ALT value 
in a substantial component (29.8%) of patients, a finding that is well 
recognised in patients with chronic hepatitis C, where typically a 
quarter can have so-called normal transaminases.[18] It highlights 
the point that ALT is a poor surrogate marker of chronic hepatitis 
C infection. Testing for hepatitis C antibody remains the screening 
test of choice and HCV RNA determination, the marker of viraemia.
During the time period under review, only a third of patients 
accessed Peg-IFN/RBV-based therapy. This finding is not unexpected 
for several reasons, including the limited funding available to 
treat patients, the significant cost of Peg-IFN/RBV treatment, the 
adverse effects of treatment and contraindications to treatment. In 
Table 2. Viral and baseline laboratory characteristics
HCV viral load (log10 IU/mL), median (IQR) 
(N=238)
5.6 (4.7 - 6.2)
GT, n (%) (N=238)
GT-1 83 (34.9)
GT-2 16 (6.7)
GT-3 43 (18.1)
GT-4 41 (17.2)
GT-5 38 (16.0)
Not tested 17 (7.1)
GT subtype, n (%)*
GT-1a 42 (17.6, 62.7)
GT-1b 25 (10.5, 37.3)
GT-2a 4 (1.7, 50.0)
GT-2b 4 (1.7, 50.0)
GT-3a 36 (15.1, 97.3)
GT-3b 1 (0.4, 2.7)
GT-4a 2 (0.8, 22.2)
GT-4c 2 (0.8, 22.2)
GT-4e 5 (2.1, 55.6)
GT-5a 30 (12.6, 100)
Not tested 17 (7.1)
Serological markers
HAV,† n (%) (N=123) 88 (71.5)
HBV,‡ n (%) (N=219) 8 (3.7)
HIV, n (%) (N=189) 31 (16.4)
 Baseline CD4+ count (cells/µL), median 
(IQR)
395 (272 - 650)
HIV/HBV/HCV§ 1 (0.4)
HCV = hepatitis C virus; IQR = interquartile range; GT = genotype; HAV = hepatitis A 
virus; IgG = immunoglobulin G; HBV = hepatitis B virus; HBsAg = hepatitis B surface 
antigen.
*Number of individuals with a genotype subtype, percentage of the total number of 
individuals (N=238), and percentage of the number of individuals subtyped within the 
genotype: GT-1 N=67, GT-2 N=8, GT-3 N=37, GT-4 N=9, GT-5 N=30.
†Hepatitis A IgG antibodies (hepatitis A immunity).
‡HBsAg (HBV co-infection).
§Triple-infected.
Table 3. Baseline laboratory characteristics of the study 
population (N=238)
Parameter
Laboratory 
reference range Median (IQR)
Total bilirubin (µmol/L) 0 - 21 10 (7 - 16)
Albumin (g/L) 35 - 52 43 (38 - 47)
ALT (U/L) 5 - 40 60 (35 - 109)
AST (U/L) 5 - 40 50 (32 - 89)
INR 0.9 - 1.2 1 (0.9 - 1.1)
Haemoglobin (g/dL) 13.0 - 17.0 14.4 (13.1 - 15.8)
White cell count (× 109/L) 4.0 - 10.0 6.2 (5 - 7.8)
Platelets (× 109/L) 137 - 373 225 (156 - 278)
Alpha-fetoprotein (µg/L) 0.0 - 7.0 3.9 (2.4 - 6.8)
Ferritin (µg/L) 30 - 400 189 (90 - 438)
IQR = interquartile range; ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; INR = international normalised ratio.
Table 5. Ancillary clinical and laboratory data (N=238)
Diabetes mellitus, n (%) 42 (17.6)
HbA1c (%), median (IQR) 7.7 (6.8 - 8.8)
Hereditary haemochromatosis (HFE genes), n (%)
C282Y heterozygous 5 (2.1)
C282Y homozygous 1 (0.4)
H63D heterozygous 19 (8.0)
H63D homozygous 1 (0.4)
Not tested 147 (61.8)
Alcohol consumption,* n (%)
Yes 39 (16.4)
No 199 (83.6)
IL28B allele, n (%)
CC 37 (15.5)
CT 57 (23.9)
TT 18 (7.6)
Not tested 126 (52.9)
*Self-reported.
Table 4. Liver biopsy results (N=238)
n (%)
Biopsies performed 90 (37.8)
Presence of steatosis (N=90) 57 (63.3)
Presence of iron (N=90) 11 (12.2)
METAVIR activity score* (N=90)
0 3 (3)
1 48 (53)
2 25 (28)
3 14 (16)
4 0
METAVIR fibrosis score† (N=90)
0 9 (10)
1 15 (16.7)
2 39 (43.3)
3 13 (14.4)
4 14 (15.6)
*0 = no active inflammation; 1 = minimal inflammation; 2 = moderate inflammation;  
3 = severe; 4 = very severe.
†0 = no fibrosis; 1 = minimal fibrosis; 2 = scarring fibrosis; 3 = bridging fibrosis;  
4 = cirrhosis.
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addition, patients with difficult-to-treat HCV genotypes or HIV 
co-infection with minimal fibrosis were ‘warehoused’ in anticipation 
of more effective therapies with fewer side-effects. The number of 
patients treated was substantial, however, and represents the single 
largest reported cohort of patients treated with Peg-IFN/RBV-based 
hepatitis C therapy in SA to date. Given that almost two-thirds of 
patients treated were the more difficult GTs 1, 4 or 5 (35.1% GT-1 
alone), almost one-third had advanced fibrosis and 10% were HIV 
co-infected, treatment outcomes in terms of SVR in 75.3% of patients 
were very good. Given that SVR rates in most large cohort studies 
ranged between 54% and 66%, our outcomes were particularly 
encouraging and several reasons probably accounted for this. Firstly, 
patient selection is important in terms of those more motivated for 
treatment and with more favourable IL28B genotypes, while the 
judicious use of supportive therapy enables maximal doses of Peg-
IFN and RBV to be used. In terms of patient selection, those with 
liver biopsies demonstrating more necro-inflammatory activity and 
greater degrees of fibrosis were more likely to be offered therapy.
Looking at the IL28B single-nucleotide polymorphism, of patients 
tested, most had the more favourable IL28B CC or CT genotype as 
opposed to the less favourable TT genotype. Data from the large 
IDEAL study were the first to demonstrate the significant predictive 
value of the relevant IL28B genotype in increasing the odds ratio in 
favour of SVR. The IL28B CC genotype resulted in an odds ratio that 
increased the likelihood of SVR 3 - 7 times.[19] In keeping with this 
finding, in our study 77% and 66%, respectively, of the CC and CT 
GT patients achieved SVR, as opposed to 40% of the TT GT patients.
Treatment outcomes are influenced by on-treatment factors such 
as achieving RVR and the ability to maintain maximum doses of 
Peg-IFN and RBV. Given the cytopenic side-effects of Peg-IFN/RBV, 
the use of GM-CSF to maintain absolute neutrophil counts and EPO 
to maintain haemoglobin levels is crucial to allow for continued 
regular administration of Peg-IFN/RBV at recommended doses.[5] 
Of our treated patients, almost a quarter (23.4%) received GM-CSF 
and/or EPO support to allow for continued dosing of Peg-IFN/RBV, 
respectively. This support enabled patients to complete the required 
duration of therapy while tolerating maximal doses and probably 
contributed to the SVR rates achieved in our cohort. Maintaining 
Peg-IFN and RBV dosing at ≥80% has a positive effect on SVR 
likelihood.[6]
Adverse events, as anticipated, were frequent. Rates of psychiatric 
adverse events, typically depression, have been reported to occur in 
5 - 20% of patients.[20,21] Just over 15% of our patients were diagnosed 
with depression that required intervention with an antidepressant 
and/or counselling and support. The rates of adverse events in our 
treated patient cohort support the difficulties of Peg-IFN/RBV-based 
therapy. Adverse effects tend to occur within first 12 weeks, so while 
duration is affected, need for support was no different between the 
two groups, viz. 24/48 weeks. We were fortunate in that only 1 patient 
discontinued therapy because of adverse events. Adverse effects were 
Table 6. PEG-IFN/RBV-treated patients: SVR according to GT distribution
GT distribution
GT-1 GT-2 GT-3 GT-4 GT-5
Total treated (N=77), n (%) 27 (35.1) 9 (11.7) 20 (26.0) 7 (9.1) 14 (18.2)
SVR, n (%) 17/27 (63) 9/9 (100) 18/20 (90.0) 4/7 (57.0) 10/14 (71.4)
No SVR, n (%) 10/27 (37) 0 2/20 (10.0) 3/7 (43.0) 4/14 (28.6)
PEG-IFN/RBV = pegylated interferon and ribavirin; SVR = sustained virological response, defined as undetectable HCV-RNA 24 weeks after the end of treatment; GT = genotype;  
HCV = hepatitis C virus.
Table 7. PEG-IFN/RBV-treated patients: liver biopsy results, 
virological response and treatment duration
n (%)
Liver biopsy results (N=49)
METAVIR activity score*
0 1 (2.0)
1 31 (63.3)
2 11 (22.5)
3 6 (12.2)
4 0
METAVIR fibrosis score†
0 5 (10.2)
1 9 (18.4)
2 21 (42.9)
3 7 (14.3)
4 7 (14.3)
Virological response (N=77)
SVR 58 (75.3)
RVR 43 (55.8)
EVR 65 (84.4)
Treatment duration (weeks) (N=77)
24 38 (49.4)
48 37 (48.1)
72 4 (5.2)
PEG-IFN/RBV = pegylated interferon and ribavirin; SVR = sustained virological  
response, defined as undetectable HCV-RNA 24 weeks after the end of treatment;  
RVR = rapid virological response, defined as an undetectable HCV-RNA at 4 weeks of 
treatment; EVR = early virological response, defined as an undetectable HCV-RNA  
or >2 log reduction of HCV-RNA at 12 weeks of treatment; HCV = hepatitis C virus.
*0 = no active inflammation; 1 = minimal inflammation; 2 = moderate inflammation;  
3 = severe; 4 = very severe.
†0 = no fibrosis; 1 = minimal fibrosis; 2 = scarring fibrosis; 3 = bridging fibrosis;  
4 = cirrhosis.
Table 8. Treatment adverse effects (N=77)
n (%)
Patients who experienced adverse effects 38 (49.4)
Patients who stopped therapy because of adverse effects 1 (1.3)
Side-effects experienced
Neutropenia 10 (11.7)
Anaemia 4 (5.2)
Thrombocytopenia 4 (5.2)
Bicytopenia 3 (3.9)
Pancytopenia 4 (5.2)
Psychiatric 7 (9.1)
Psychiatric and cytopenia 5 (6.5)
Rash 1 (2.6)
Cell support required
EPO 6 (7.8)
GM-CSF 6 (7.8)
EPO + GM-CSF 6 (7.8)
EPO = erythropoietin; GM-CSF = granulocyte-macrophage colony-stimulating factor.
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compounded in patients using the add-on PI therapy, telaprevir. 
While numbers were small, 80% of GT-1 patients using telaprevir in 
conjunction with Peg-IFN/RBV achieved SVR.
Study limitations
With regard to study limitations, this was a retrospective study and 
not all required data were available. IL28B genotyping only became 
available in 2011. Resource constraints resulted in a limited number 
of patients being treated, and very careful selection was required to 
ensure that those treated had the greatest likelihood of cure. This 
selection bias may have inflated SVR rates. There may be under-
representation of certain high-risk populations such as IDUs, because 
they are less likely to present or be referred.
Conclusions
The HCV patient population in the Peg-IFN/RBV era in our clinic 
represented the more typical epidemiology of HCV acquisition, 
either via previous IDU or blood transfusion prior to 1992. Notably, 
our patient population is pangenotypic in GT distribution, and our 
treatment outcomes during this era were commendable despite 
significant treatment challenges and adverse events. Careful patient 
selection, favourable IL28B alleles and sensible cytopenia support 
as well as on-treatment responses with high rates of RVR and 
EVR probably account for these good results. Our study is the first 
to document outcomes of interferon-based therapy for hepatitis 
C in SA. It will serve as a benchmark for comparison with the 
performance of DAAs in SA. Given the need for data in informing 
national policy decision-making structures and the fact that no 
such data exist, this study serves to inform and support such policy 
structures, and encourage government to provide the economic 
infrastructure required to support SA’s effort for viral hepatitis 
elimination by 2030, in which DAA therapy for hepatitis C will be the 
foundation of management.
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